- Home
- IIPR vs AUPH Comparison
IIPR vs AUPH Comparison
Compare IIPR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIPR
- AUPH
- Stock Information
- Founded
- IIPR 2016
- AUPH 1993
- Country
- IIPR United States
- AUPH Canada
- Employees
- IIPR N/A
- AUPH N/A
- Industry
- IIPR Real Estate
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- IIPR Finance
- AUPH Health Care
- Exchange
- IIPR Nasdaq
- AUPH Nasdaq
- Market Cap
- IIPR 1.5B
- AUPH 1.4B
- IPO Year
- IIPR 2016
- AUPH 1999
- Fundamental
- Price
- IIPR $54.69
- AUPH $11.74
- Analyst Decision
- IIPR Hold
- AUPH Strong Buy
- Analyst Count
- IIPR 8
- AUPH 2
- Target Price
- IIPR $88.75
- AUPH $13.00
- AVG Volume (30 Days)
- IIPR 322.6K
- AUPH 1.9M
- Earning Date
- IIPR 11-05-2025
- AUPH 11-06-2025
- Dividend Yield
- IIPR 13.85%
- AUPH N/A
- EPS Growth
- IIPR N/A
- AUPH N/A
- EPS
- IIPR 4.63
- AUPH 0.42
- Revenue
- IIPR $287,883,000.00
- AUPH $260,111,000.00
- Revenue This Year
- IIPR N/A
- AUPH $17.33
- Revenue Next Year
- IIPR N/A
- AUPH $14.31
- P/E Ratio
- IIPR $11.84
- AUPH $27.86
- Revenue Growth
- IIPR N/A
- AUPH 25.59
- 52 Week Low
- IIPR $45.44
- AUPH $6.55
- 52 Week High
- IIPR $136.81
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- IIPR 48.42
- AUPH 46.50
- Support Level
- IIPR $51.96
- AUPH $11.18
- Resistance Level
- IIPR $58.10
- AUPH $11.70
- Average True Range (ATR)
- IIPR 1.68
- AUPH 0.66
- MACD
- IIPR -0.16
- AUPH -0.18
- Stochastic Oscillator
- IIPR 44.02
- AUPH 42.50
About IIPR Innovative Industrial Properties Inc.
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.